Science
Alzheimer's Drug Lecanemab Shows 27% Cognitive Decline Reduction in Major Clinical Trial
Lecanemab shows 27% reduction in cognitive decline for early Alzheimer's patients. The breakthrough could transform dementia treatment worldwide.
2 articles
Lecanemab shows 27% reduction in cognitive decline for early Alzheimer's patients. The breakthrough could transform dementia treatment worldwide.
Clinical trial results show gene therapy successfully restoring partial vision in patients with hereditary blindness. The breakthrough treatment could revolutionize care for inherited eye diseases.